KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Operating Margin (2016 - 2025)

Vertex Pharmaceuticals has reported Operating Margin over the past 17 years, most recently at 37.8% for Q4 2025.

  • Quarterly results put Operating Margin at 37.8% for Q4 2025, up 257.0% from a year ago — trailing twelve months through Dec 2025 was 34.77% (up 3689.0% YoY), and the annual figure for FY2025 was 34.77%, up 3689.0%.
  • Operating Margin for Q4 2025 was 37.8% at Vertex Pharmaceuticals, down from 38.56% in the prior quarter.
  • Over the last five years, Operating Margin for VRTX hit a ceiling of 53.15% in Q3 2021 and a floor of 132.85% in Q2 2024.
  • Median Operating Margin over the past 5 years was 40.72% (2023), compared with a mean of 30.8%.
  • Biggest five-year swings in Operating Margin: tumbled -17402bps in 2024 and later soared 17168bps in 2025.
  • Vertex Pharmaceuticals' Operating Margin stood at 42.35% in 2021, then increased by 6bps to 44.88% in 2022, then dropped by -13bps to 39.26% in 2023, then dropped by -10bps to 35.23% in 2024, then increased by 7bps to 37.8% in 2025.
  • The last three reported values for Operating Margin were 37.8% (Q4 2025), 38.56% (Q3 2025), and 38.83% (Q2 2025) per Business Quant data.